drugset
drugset / Trial / NCT03775434

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

NCT03775434 ↗

Phase 1 Completed 28 enrolled AOBiome LLC Novella Clinical · collab
NaSingle-groupOpen-labelTreatment

Summary

An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b

Timeline

Start
2018-12-07
Primary completion
2019-05-18
Completion
2019-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject B244 Other / unclassified — Topical

Indications

atopic eczema